帕尼单抗-话题@MedSci

#帕尼单抗#

16篇内容 | 1025人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2189033, encodeId=15db218903369, content=<a href='/topic/show?id=f9ba484920f' target=_blank style='color:#2F92EE;'>#帕尼单抗#</a> <a href='/topic/show?id=18d293422fd' target=_blank style='color:#2F92EE;'>#转移性结直肠癌#</a> <a href='/topic/show?id=1438105e47a1' target=_blank style='color:#2F92EE;'>#KRAS G12C突变#</a> <a href='/topic/show?id=b64e106e80cc' target=_blank style='color:#2F92EE;'>#索托拉西布#</a>, objectTitle=Nat. Med | 索托拉西布联合帕尼单抗治疗化疗难治性KRAS G12C突变结直肠癌：一项1b期试验, objectType=article, longId=814485, objectId=fe0781448562, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240223/1708692776997_6145188.png, objectUrl=/article/show_article.do?id=fe0781448562, replyNumber=0, likeNumber=23, createdTime=2024-02-24, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=fe0781448562, moduleTitle=Nat. Med | 索托拉西布联合帕尼单抗治疗化疗难治性KRAS G12C突变结直肠癌：一项1b期试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fe0781448562)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2184449, encodeId=e98d2184449ed, content=<a href='/topic/show?id=adf23354483' target=_blank style='color:#2F92EE;'>#化疗#</a> <a href='/topic/show?id=493ae869206' target=_blank style='color:#2F92EE;'>#结直肠癌#</a> <a href='/topic/show?id=f9ba484920f' target=_blank style='color:#2F92EE;'>#帕尼单抗#</a> <a href='/topic/show?id=c07b110634bb' target=_blank style='color:#2F92EE;'>#索托雷塞#</a>, objectTitle=Nat Med：化疗难治性KRAS G12C结直肠癌应用索托雷塞+帕尼单抗，最新数据公布, objectType=article, longId=811356, objectId=795d81135617, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20221109/1668016299208_4754896.png, objectUrl=/article/show_article.do?id=795d81135617, replyNumber=0, likeNumber=28, createdTime=2024-01-28, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=795d81135617, moduleTitle=Nat Med：化疗难治性KRAS G12C结直肠癌应用索托雷塞+帕尼单抗，最新数据公布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=795d81135617)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2165823, encodeId=5e0c2165823d0, content=治疗<a href='/topic/show?id=1438105e47a1' target=_blank style='color:#2F92EE;'>#KRAS G12C突变#</a>的难治性<a href='/topic/show?id=493ae869206' target=_blank style='color:#2F92EE;'>#结直肠癌#</a>患者，经过中位7.8个月随访，960 mg<a href='/topic/show?id=b64e106e80cc' target=_blank style='color:#2F92EE;'>#索托拉西布#</a>+<a href='/topic/show?id=f9ba484920f' target=_blank style='color:#2F92EE;'>#帕尼单抗#</a>组和240 mg索托拉西布+帕尼单抗组的中位无进展生存期分别为5.6个月和3.9个月，而标准治疗组为2.2个月。整体而言，治疗的难度还是相当大的，对这些难治性的，未来还需要更多的手段。, objectTitle=NEJM：治疗KRAS G12C突变的难治性结直肠癌患者，索托拉西布联合帕尼单抗或可延长无进展生存期, objectType=article, longId=798509, objectId=5a81e9850934, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/202301009/1696894056775_4754896.jpeg, objectUrl=/article/show_article.do?id=5a81e9850934, replyNumber=0, likeNumber=45, createdTime=2023-10-31, rootId=0, userName=侠胆医心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=加利福尼亚, moduleDTOList=[ModuleDTO(moduleId=5a81e9850934, moduleTitle=NEJM：治疗KRAS G12C突变的难治性结直肠癌患者，索托拉西布联合帕尼单抗或可延长无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5a81e9850934)], followStatus=false, userIsMember=true, type=1, lengthMark=1), GetTopicListResponse(id=1394246, encodeId=13131394246e5, content=<a href='/topic/show?id=f9ba484920f' target=_blank style='color:#2F92EE;'>#帕尼单抗#</a>, objectTitle=J Clin Oncol：mFOLFOXIRI+帕尼单抗对比FOLFOX+帕尼单抗一线治疗RAS和BRAF野生型转移性结直肠癌(mCRC)的疗效, objectType=article, longId=729659, objectId=add1e2965928, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=add1e2965928, replyNumber=0, likeNumber=31, createdTime=2022-06-17, rootId=0, userName=12498c24m69暂无昵称, userId=1dfd2500156, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=add1e2965928, moduleTitle=J Clin Oncol：mFOLFOXIRI+帕尼单抗对比FOLFOX+帕尼单抗一线治疗RAS和BRAF野生型转移性结直肠癌(mCRC)的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=add1e2965928)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1394245, encodeId=03831394245ec, content=<a href='/topic/show?id=f9ba484920f' target=_blank style='color:#2F92EE;'>#帕尼单抗#</a>, objectTitle=J Clin Oncol：mFOLFOXIRI方案联合帕尼单抗治疗RAS/BRAF野生型转移性结直肠癌, objectType=article, longId=729558, objectId=3e05e29558cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3e05e29558cc, replyNumber=0, likeNumber=43, createdTime=2022-06-16, rootId=0, userName=12498c24m69暂无昵称, userId=1dfd2500156, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3e05e29558cc, moduleTitle=J Clin Oncol：mFOLFOXIRI方案联合帕尼单抗治疗RAS/BRAF野生型转移性结直肠癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3e05e29558cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1394244, encodeId=4073139424470, content=<a href='/topic/show?id=f9ba484920f' target=_blank style='color:#2F92EE;'>#帕尼单抗#</a>, objectTitle=J Clin Oncol：氟尿嘧啶/亚叶酸联合帕尼单抗维持治疗可显著延长RAS野生型转移性结直肠癌患者的生存期, objectType=article, longId=221344, objectId=e1b922134447, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e1b922134447, replyNumber=0, likeNumber=0, createdTime=2021-12-02, rootId=0, userName=12498c24m69暂无昵称, userId=1dfd2500156, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e1b922134447, moduleTitle=J Clin Oncol：氟尿嘧啶/亚叶酸联合帕尼单抗维持治疗可显著延长RAS野生型转移性结直肠癌患者的生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e1b922134447)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1394243, encodeId=28a613942435a, content=<a href='/topic/show?id=f9ba484920f' target=_blank style='color:#2F92EE;'>#帕尼单抗#</a>, objectTitle=J Clin Oncol：氟尿嘧啶/亚叶酸联合帕尼单抗维持治疗可显著延长RAS野生型转移性结直肠癌患者的生存期, objectType=article, longId=217301, objectId=986821e3019a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=986821e3019a, replyNumber=0, likeNumber=31, createdTime=2021-09-20, rootId=0, userName=12498c24m69暂无昵称, userId=1dfd2500156, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=986821e3019a, moduleTitle=J Clin Oncol：氟尿嘧啶/亚叶酸联合帕尼单抗维持治疗可显著延长RAS野生型转移性结直肠癌患者的生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=986821e3019a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1394242, encodeId=edae139424223, content=<a href='/topic/show?id=f9ba484920f' target=_blank style='color:#2F92EE;'>#帕尼单抗#</a>, objectTitle=NEJM：帕尼单抗相关的睫毛伸长-病例报道, objectType=article, longId=202125, objectId=4fb720212520, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4fb720212520, replyNumber=0, likeNumber=43, createdTime=2020-10-16, rootId=0, userName=12498c24m69暂无昵称, userId=1dfd2500156, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4fb720212520, moduleTitle=NEJM：帕尼单抗相关的睫毛伸长-病例报道, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4fb720212520)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1394241, encodeId=1d151394241b9, content=<a href='/topic/show?id=f9ba484920f' target=_blank style='color:#2F92EE;'>#帕尼单抗#</a>, objectTitle=Medicine：帕尼单抗补充治疗可一定程度上改善WT KRAS的结直肠癌患者的客观反应，但会增加不良事件的发生率, objectType=article, longId=198620, objectId=2e5e19862046, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2e5e19862046, replyNumber=0, likeNumber=43, createdTime=2020-08-04, rootId=0, userName=12498c24m69暂无昵称, userId=1dfd2500156, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2e5e19862046, moduleTitle=Medicine：帕尼单抗补充治疗可一定程度上改善WT KRAS的结直肠癌患者的客观反应，但会增加不良事件的发生率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2e5e19862046)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1394240, encodeId=ed70139424062, content=<a href='/topic/show?id=f9ba484920f' target=_blank style='color:#2F92EE;'>#帕尼单抗#</a>, objectTitle=JAMA Oncol：VALENTINO研究：帕尼单抗一线维持治疗RAS野生型结直肠癌劣于帕尼单抗联合氟尿嘧啶, objectType=article, longId=175430, objectId=98161e54306c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=98161e54306c, replyNumber=0, likeNumber=35, createdTime=2019-07-16, rootId=0, userName=12498c24m69暂无昵称, userId=1dfd2500156, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=98161e54306c, moduleTitle=JAMA Oncol：VALENTINO研究：帕尼单抗一线维持治疗RAS野生型结直肠癌劣于帕尼单抗联合氟尿嘧啶, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=98161e54306c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1394239, encodeId=479e13942397f, content=<a href='/topic/show?id=f9ba484920f' target=_blank style='color:#2F92EE;'>#帕尼单抗#</a>, objectTitle=CLIN CANCER RES：循环肿瘤DNA出现RAS紧急突变对帕尼单抗治疗转移性结直肠癌的影响, objectType=article, longId=154235, objectId=dc0a1542358e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dc0a1542358e, replyNumber=0, likeNumber=35, createdTime=2018-11-24, rootId=0, userName=12498c24m69暂无昵称, userId=1dfd2500156, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dc0a1542358e, moduleTitle=CLIN CANCER RES：循环肿瘤DNA出现RAS紧急突变对帕尼单抗治疗转移性结直肠癌的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dc0a1542358e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1394238, encodeId=58bf1394238dd, content=<a href='/topic/show?id=f9ba484920f' target=_blank style='color:#2F92EE;'>#帕尼单抗#</a>, objectTitle=EUR J Cancer：帕尼单抗联合顺铂/吉西他滨治疗KRAS野生型胆管癌, objectType=article, longId=131020, objectId=199e13102034, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=199e13102034, replyNumber=0, likeNumber=40, createdTime=2018-03-02, rootId=0, userName=12498c24m69暂无昵称, userId=1dfd2500156, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=199e13102034, moduleTitle=EUR J Cancer：帕尼单抗联合顺铂/吉西他滨治疗KRAS野生型胆管癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=199e13102034)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1394237, encodeId=c1aa139423e69, content=<a href='/topic/show?id=f9ba484920f' target=_blank style='color:#2F92EE;'>#帕尼单抗#</a>, objectTitle=Br J Cancer：野生型KRAS或RAS转移性结直肠癌：帕尼单抗联合更佳支持治疗, objectType=article, longId=80610, objectId=9e8d8061024, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9e8d8061024, replyNumber=0, likeNumber=37, createdTime=2016-10-22, rootId=0, userName=12498c24m69暂无昵称, userId=1dfd2500156, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9e8d8061024, moduleTitle=Br J Cancer：野生型KRAS或RAS转移性结直肠癌：帕尼单抗联合更佳支持治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9e8d8061024)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1394236, encodeId=871213942368c, content=<a href='/topic/show?id=f9ba484920f' target=_blank style='color:#2F92EE;'>#帕尼单抗#</a>, objectTitle=Clin Cancer Res：帕尼单抗联合吉西他滨放化疗用于局部晚期胰腺癌的I期临床研究, objectType=article, longId=52061, objectId=5d9d520619e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5d9d520619e, replyNumber=0, likeNumber=33, createdTime=2015-06-15, rootId=0, userName=12498c24m69暂无昵称, userId=1dfd2500156, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5d9d520619e, moduleTitle=Clin Cancer Res：帕尼单抗联合吉西他滨放化疗用于局部晚期胰腺癌的I期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5d9d520619e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1394235, encodeId=25fb139423509, content=<a href='/topic/show?id=f9ba484920f' target=_blank style='color:#2F92EE;'>#帕尼单抗#</a>, objectTitle=Lancet Oncol：二期临床发现帕尼单抗不适用于晚期头颈部鳞癌, objectType=article, longId=46053, objectId=5ebb46053a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5ebb46053a6, replyNumber=0, likeNumber=32, createdTime=2015-01-25, rootId=0, userName=12498c24m69暂无昵称, userId=1dfd2500156, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5ebb46053a6, moduleTitle=Lancet Oncol：二期临床发现帕尼单抗不适用于晚期头颈部鳞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5ebb46053a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1394234, encodeId=751c139423420, content=<a href='/topic/show?id=f9ba484920f' target=_blank style='color:#2F92EE;'>#帕尼单抗#</a>, objectTitle=CCC：帕尼单抗或贝伐单抗联合FOLFIRI方案二线治疗转移性结直肠癌疗效比较(SPIRITT研究）, objectType=article, longId=45314, objectId=88b5453142a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=88b5453142a, replyNumber=0, likeNumber=38, createdTime=2015-01-12, rootId=0, userName=12498c24m69暂无昵称, userId=1dfd2500156, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=88b5453142a, moduleTitle=CCC：帕尼单抗或贝伐单抗联合FOLFIRI方案二线治疗转移性结直肠癌疗效比较(SPIRITT研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=88b5453142a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1394233, encodeId=02f71394233b2, content=<a href='/topic/show?id=f9ba484920f' target=_blank style='color:#2F92EE;'>#帕尼单抗#</a>, objectTitle=Int J Radiat Oncol Biol Phys：术前放化疗结合帕尼单抗治疗可切除食管癌：2期临床试验, objectType=article, longId=42694, objectId=ffe84269456, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ffe84269456, replyNumber=0, likeNumber=43, createdTime=2014-11-19, rootId=0, userName=12498c24m69暂无昵称, userId=1dfd2500156, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ffe84269456, moduleTitle=Int J Radiat Oncol Biol Phys：术前放化疗结合帕尼单抗治疗可切除食管癌：2期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ffe84269456)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1394232, encodeId=e7ba13942322a, content=<a href='/topic/show?id=f9ba484920f' target=_blank style='color:#2F92EE;'>#帕尼单抗#</a>, objectTitle=Lancet Oncol：帕尼单抗对KRAS野生型转移性结直肠癌非劣于西妥昔单抗（ASPECCT研究）, objectType=article, longId=33909, objectId=cae8339099f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cae8339099f, replyNumber=0, likeNumber=27, createdTime=2014-04-30, rootId=0, userName=12498c24m69暂无昵称, userId=1dfd2500156, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cae8339099f, moduleTitle=Lancet Oncol：帕尼单抗对KRAS野生型转移性结直肠癌非劣于西妥昔单抗（ASPECCT研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cae8339099f)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

帕尼单抗

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#帕尼单抗# #转移性结直肠癌# #KRAS G12C突变# #索托拉西布#

Nat. Med | 索托拉西布联合帕尼单抗治疗化疗难治性KRAS G12C突变结直肠癌：一项1b期试验

2024-02-24发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#化疗# #结直肠癌# #帕尼单抗# #索托雷塞#

Nat Med：化疗难治性KRAS G12C结直肠癌应用索托雷塞+帕尼单抗，最新数据公布

2024-01-28发表于陕西省

(审核中...)

前往app查看评论内容

全文收起治疗#KRAS G12C突变#的难治性#结直肠癌#患者，经过中位7.8个月随访，960 mg#索托拉西布#+#帕尼单抗#组和240 mg索托拉西布+帕尼单抗组的中位无进展生存期分别为5.6个月和3.9个月，而标准治疗组为2.2个月。整体而言，治疗的难度还是相当大的，对这些难治性的，未来还需要更多的手段。

NEJM：治疗KRAS G12C突变的难治性结直肠癌患者，索托拉西布联合帕尼单抗或可延长无进展生存期

2023-10-31发表于加利福尼亚

12498c24m69暂无昵称 (审核中...)

前往app查看评论内容

#帕尼单抗#

J Clin Oncol：mFOLFOXIRI+帕尼单抗对比FOLFOX+帕尼单抗一线治疗RAS和BRAF野生型转移性结直肠癌(mCRC)的疗效

2022-06-17

12498c24m69暂无昵称 (审核中...)

前往app查看评论内容

#帕尼单抗#

J Clin Oncol：mFOLFOXIRI方案联合帕尼单抗治疗RAS/BRAF野生型转移性结直肠癌

2022-06-16

12498c24m69暂无昵称 (审核中...)

前往app查看评论内容

#帕尼单抗#

J Clin Oncol：氟尿嘧啶/亚叶酸联合帕尼单抗维持治疗可显著延长RAS野生型转移性结直肠癌患者的生存期

2021-12-02

12498c24m69暂无昵称 (审核中...)

前往app查看评论内容

#帕尼单抗#

J Clin Oncol：氟尿嘧啶/亚叶酸联合帕尼单抗维持治疗可显著延长RAS野生型转移性结直肠癌患者的生存期

2021-09-20

12498c24m69暂无昵称 (审核中...)

前往app查看评论内容

#帕尼单抗#

NEJM：帕尼单抗相关的睫毛伸长-病例报道

2020-10-16

12498c24m69暂无昵称 (审核中...)

前往app查看评论内容

#帕尼单抗#

Medicine：帕尼单抗补充治疗可一定程度上改善WT KRAS的结直肠癌患者的客观反应，但会增加不良事件的发生率

2020-08-04

12498c24m69暂无昵称 (审核中...)

前往app查看评论内容

#帕尼单抗#

JAMA Oncol：VALENTINO研究：帕尼单抗一线维持治疗RAS野生型结直肠癌劣于帕尼单抗联合氟尿嘧啶

2019-07-16

12498c24m69暂无昵称 (审核中...)

前往app查看评论内容

#帕尼单抗#

CLIN CANCER RES：循环肿瘤DNA出现RAS紧急突变对帕尼单抗治疗转移性结直肠癌的影响

2018-11-24

12498c24m69暂无昵称 (审核中...)

前往app查看评论内容

#帕尼单抗#

EUR J Cancer：帕尼单抗联合顺铂/吉西他滨治疗KRAS野生型胆管癌

2018-03-02

12498c24m69暂无昵称 (审核中...)

前往app查看评论内容

#帕尼单抗#

Br J Cancer：野生型KRAS或RAS转移性结直肠癌：帕尼单抗联合更佳支持治疗

2016-10-22

12498c24m69暂无昵称 (审核中...)

前往app查看评论内容

#帕尼单抗#

Clin Cancer Res：帕尼单抗联合吉西他滨放化疗用于局部晚期胰腺癌的I期临床研究

2015-06-15

12498c24m69暂无昵称 (审核中...)

前往app查看评论内容

#帕尼单抗#

Lancet Oncol：二期临床发现帕尼单抗不适用于晚期头颈部鳞癌

2015-01-25

12498c24m69暂无昵称 (审核中...)

前往app查看评论内容

#帕尼单抗#

CCC：帕尼单抗或贝伐单抗联合FOLFIRI方案二线治疗转移性结直肠癌疗效比较(SPIRITT研究）

2015-01-12

12498c24m69暂无昵称 (审核中...)

前往app查看评论内容

#帕尼单抗#

Int J Radiat Oncol Biol Phys：术前放化疗结合帕尼单抗治疗可切除食管癌：2期临床试验

2014-11-19

12498c24m69暂无昵称 (审核中...)

前往app查看评论内容

#帕尼单抗#

Lancet Oncol：帕尼单抗对KRAS野生型转移性结直肠癌非劣于西妥昔单抗（ASPECCT研究）

2014-04-30

科室
- - 订阅+
  - 更多科室
工具
服务